Enveric Biosciences, Inc.
- ENVB
- NASDAQ
- Biotechnology
- Cannabinoid Therapeutics
- Cancer Supportive Care
- Clinical-stage Pharma
$1.41
Today +2.17%Quote Oct 19, 2026, 07:59 PM UTC
−12.96%over the last month
Max drawdown −15.4%From 1-month high −13.0%3 months +6.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
6
Market value
$6.3M
Quote Oct 19
Floor
$1.36
3.5% below price
Resistance
$1.42
0.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ENVBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free